Phoenix Holdings Ltd. Vertex Pharmaceuticals Inc Transaction History

Phoenix Holdings Ltd.

$6.66 Billion
Q3 2024

A detailed history of Phoenix Holdings Ltd. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Phoenix Holdings Ltd. holds 2,281 shares of VRTX stock, worth $1.03 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,281

Previous 4,489 49.19%

Holding current value

$1.03 Million

Previous $2.1 Million 49.62%

% of portfolio

0.02%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$460.0 - $505.78 $1.02 Million - $1.12 Million	-2,208 Reduced 49.19%	2,281 $1.06 Million
Q2 2024 Aug 12, 2024	SELL	$392.81 - $485.53 $215,259 - $266,070	-548 Reduced 10.88%	4,489 $2.1 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $1.41 Million - $1.55 Million	3,467 Added 220.83%	5,037 $2.11 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $538,510 - $644,767	1,570 New	1,570 $638,000
Q3 2022 Nov 10, 2022	SELL	$273.83 - $305.53 $271,091 - $302,474	-990 Reduced 26.64%	2,726 $806,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $1.16 Million - $1.45 Million	-4,944 Reduced 57.09%	3,716 $1.03 Million
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $527,422 - $621,630	-2,382 Reduced 21.57%	8,660 $2.23 Million
Q4 2021 Feb 07, 2022	SELL	$177.01 - $223.45 $223,032 - $281,547	-1,260 Reduced 10.24%	11,042 $2.47 Million
Q3 2021 Oct 27, 2021	BUY	$181.39 - $202.99 $273,173 - $305,702	1,506 Added 13.95%	12,302 $2.24 Million
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $356,231 - $420,090	1,900 Added 21.36%	10,796 $2.12 Million
Q1 2021 May 10, 2021	BUY	$207.02 - $241.31 $1.84 Million - $2.15 Million	8,896 New	8,896 $1.9 Million

Others Institutions Holding VRTX

# of Institutions

1,721

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Phoenix Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Phoenix Holdings Ltd. with notifications on news.

Account

Phoenix Holdings Ltd. Vertex Pharmaceuticals Inc Transaction History